{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-197957","form_type":"8-K","ticker":"ACAD","cik":"0001070494","company_name":"ACADIA PHARMACEUTICALS INC","filed_at":"2026-05-01T23:59:59+00:00","discovered_at":"2026-05-14T18:02:31.908336+00:00","generated_at":"2026-05-15T00:13:05.696301+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Acadia R&D Head Elizabeth Thompson plans retirement; stays through 2026 as consultant","bullets":["Dr. Thompson will retire for personal reasons; remains as Head of R&D until successor appointed, then consultant through end of 2026.","She will stay through readout of Phase 2 remlifanserin in Alzheimer's disease psychosis and into early Phase 3.","Company has initiated a search for a new Head of R&D; all ongoing clinical trials continue as planned.","Thompson joined Acadia in 2024 and helped strengthen clinical capabilities and advance pipeline programs."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-197957","json":"https://secwatch.observer/filing/0001193125-26-197957.json","markdown":"https://secwatch.observer/filing/0001193125-26-197957.md","text":"https://secwatch.observer/filing/0001193125-26-197957.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1070494/000119312526197957/0001193125-26-197957-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1070494/000119312526197957/acad-20260427.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T00:13:05.696301+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"254a906104","claim":"Elizabeth H.Z. Thompson retired as Head of Research and Development at ACADIA PHARMACEUTICALS INC.","evidence_excerpt":"On April 27, 2026, Elizabeth H.Z. Thompson, Ph.D., Head of Research and Development, informed Acadia Pharmaceuticals Inc. (the “Company”) of her planned retirement.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1070494/000119312526197957/0001193125-26-197957-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"retired"},{"label":"Role","value":"Head of Research and Development"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}